Phase Ib pancreatic cancer data demonstrate Halozyme hyaluronan thesis
This article was originally published in Scrip
Progression-free survival (PFS) was twice as high and overall survival was three times as high for pancreatic cancer patients with high levels of tumor-associated hyaluronan (HA) who were treated with Halozyme Therapeutics's PEGPH20 (pegylated recombinant human hyaluronidase) plus gemcitabine than for patients whose tumors had low HA levels in a Phase Ib clinical trial.
You may also be interested in...
Halozyme CEO Helen Torley spoke with Scrip about execution of the company's strategy – reworked after her arrival in 2014 – to focus on oncology drug development and partnerships using its Enhanze platform.
The amyloid-targeting drug is years behind Biogen/Eisai’s aducanumab, but its subcutaneous administration and the GRADUATE studies’ design could give Roche’s gantenerumab an advantage.
Biogen presented highly anticipated data in Alzheimer’s disease at CTAD for its Phase III EMERGE and ENGAGE studies, but one major question remains unanswered: will the FDA approve the drug?